

Unaudited Financial Results for the Quarter ended February 28, 2005

Sr. No.	Particulars	Rs. in Million		
		3 months ended February 28, 2005 (Unaudited)	3 months ended February 29, 2004 (Unaudited)	Year ended November 30, 2004 (Audited)
1	Net Sales	897.3	929.5	4050.7
2	Other Income	31.1	75.5	520.0
3	Total Expenditure	735.4	732.2	3152.8
	a) (Increase)/decrease in stock in trade	(93.4)	20.7	36.1
	b) Consumption of raw materials	17.0	44.7	147.9
	c) Staff Cost	61.6	60.6	243.9
	d) Other Expenditure			
	(i.) Purchase of Finished Goods	635.8	507.8	2306.1
	(ii.) Others	114.4	98.4	418.8
4	Interest	0.1	0.1	1.7
5	Depreciation	8.9	10.0	41.7
6	Profit before Tax	184.0	262.7	1374.5
7	Provision for Taxation (including deferred taxation and prior years)	56.6	68.4	352.0
8	Net Profit	127.4	194.3	1022.5
9	Paid- up Equity Share Capital (face value of the share – Rs. 10).	152.8	152.8	152.8
10	Reserves excluding revaluation reserves (as per balance sheet)	-	-	1730.0
11	Basic and diluted Earnings per share – Rs.	8.34	12.72	66.92
12	Aggregate of non promoting shareholding			
	Number of Shares	5,851,916	5,851,916	5,851,916
	Percentage of Shareholding	38.3%	38.3%	38.3%

Notes :

- Sales were impacted in the quarter mainly due to uncertainties caused by the transition to Value Added Tax (VAT) regime.
- The Company operates mainly in the pharmaceuticals segment.
- Other income for the quarter ended 28 February 2005 includes profit on sale of Units of Mutual Funds Rs. 1.5 million (Quarter ended 29 February 2004: Rs. 58.2 million).
- The results for the quarter ended 28 February 2005 have been subjected to a "Limited Review" by the auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors, in compliance with the provisions of the Listing Agreement with The Stock Exchange, Mumbai.
- There were no Investor Complaints pending at the beginning of the quarter. The company received 7 complaints from the investors and all the complaints were resolved and disposed of during the quarter. There were no complaints lying unresolved at the end of the quarter.
- Figures for the prior year have been regrouped and/or reclassified wherever considered necessary.

Abbott India Limited

Vivek Mohan
Managing Director

Mumbai: 22 March 2005